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Disruption of mitochondrial homeostasis is a hallmark of cardiac diseases. Therefore,
maintenance of mitochondrial integrity through different surveillance mechanisms is
critical for cardiomyocyte survival. In this review, we discuss the most recent findings
on the central role of mitochondrial quality control processes including regulation
of mitochondrial redox balance, aldehyde metabolism, proteostasis, dynamics, and
clearance in cardiac diseases, highlighting their potential as therapeutic targets.
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INTRODUCTION
Cardiac disease remains the leading cause of morbidity and mortality worldwide (Bayeva et al.,
2013). Despite the fact that the mechanisms underlying the pathophysiology of heart disease are
multiple and complex, recent research provides evidence that loss of mitochondrial homeostasis is
a hallmark of cardiomyocyte dysfunction and death (Disatnik et al., 2013; Yogalingam et al., 2013).
Mitochondria are critical organelles for the maintenance of cardiac physiology since
cardiomyocytes have a high demand for ATP synthesis and increased oxygen uptake rate. These
mitochondrial features also make them the major source of reactive oxygen species (ROS)
under pathological circumstances (Figueira et al., 2013). Indeed, disruption of mitochondrial
electrochemical and redox properties is tightly associated with the onset and progression of cardiac
pathophysiology (Palaniyandi et al., 2010; Gomes et al., 2015). Despite of their main role in ensuring
that cardiac energy demands aremet by energy supply, mitochondria have been lately highlighted as
strategic intracellular nodes/transducers where signals converge. Mitochondria also serve as multi
effector players in a wide range of intracellular signaling pathways that ultimately regulates nuclear
gene expression, ions homeostasis, and apoptosis (Campos et al., 2013).
Considering the pivotal role of mitochondria in regulating intracellular homeostasis, eukaryotic
cells have developed several mechanisms of surveillance capable of maintaining mitochondrial
integrity and functionality upon stress (Baker et al., 2011; Kotiadis et al., 2014). These
quality control machineries can be divided into three levels of surveillance. The first level of
defense involves a multilayer network of detoxifying systems capable of fighting oxygen- and
aldehyde-mediated mitochondrial toxicity. The second line of defense relies to mitochondrial
proteases and chaperones responsible for the maintenance of mitochondrial proteostasis. The
third level of defense involves the control of mitochondrial morphology and number through
two interconnected processes: mitochondrial dynamics (fusion and fission) and mitophagy
(mitochondrial clearance). These three levels of defense are well-conserved quality control
mechanisms capable of regulating mitochondrial redox state, content, size and number due to
changes in mitochondrial bioenergetics, biochemical, or electrochemical properties (Twig et al.,
2008).
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In this review, we will approach the aforementioned
mechanisms of mitochondrial surveillance and defense in health
and cardiac diseases; highlighting their critical role in the
maintenance of cardiac homeostasis.
MITOCHONDRIAL DETOXIFYING
SYSTEMS (FIRST LEVEL OF DEFENSE)
Detoxifying systems are critical mitochondrial quality control
mechanisms that provide protection from biogenic and
xenogeneic molecules such as ROS and aldehydes.
The term oxidative stress describes conditions that result
from the imbalance between free radical generation and its
detoxification. Aerobic organisms have developed a series of
antioxidant defenses, including antioxidant compounds and
enzymes that directly react with and neutralize oxidizing
agents; thereforeminimizing the oxidative stress-induced cellular
damage (Kornfeld et al., 2015).
Mitochondria are the main source of cellular ROS as well
as have the highest antioxidant capacity (Figueira et al., 2013).
Accumulation of mitochondrial ROS is critical to cardiac
ischemia-reperfusion injury and heart failure (Campos et al.,
2012, 2013; Chouchani et al., 2014). The use of experimental
animal models has contributed to the understanding of the
role of antioxidant system as a first line of defense against the
pathogenesis of cardiac diseases. SOD deficiency has been linked
to excessive ROS accumulation and cardiac mitochondrial
dysfunction, thus contributing to the establishment of
pathological ventricular hypertrophy and heart failure in
mice (Strassburger et al., 2005; Morten et al., 2006; Lu et al.,
2008). Moreover, cardiac overexpression of either MnSOD or
Cu-ZnSOD isoforms attenuates cardiac ischemia-reperfusion
injury and heart failure in mice (Chen et al., 1998; Miller et al.,
2010).
In general, enhanced activity of enzymatic antioxidants
(i.e., catalase, glutathione peroxidase, thioredoxin, and
peroxiredoxin) or increased levels of non-enzymatic antioxidants
(i.e., glutathione, N-acetylcysteine, ubiquinol, α-tocopherol,
ascorbic acid, and lipoic acid) reduce cardiac oxidative
stress in rodents by maintaining ROS at nanomolar levels
(Goszcz et al., 2015). However, these findings have not been
reproduced in randomized controlled trial (Kritharides and
Stocker, 2002; Ye et al., 2013). One possible explanation for
the failure in clinical trials relies to the inability of these
antioxidants to properly counteract mitochondrial oxidative
stress. Recent studies have demonstrated that the development
of antioxidants that are target to and selectively accumulates
within mitochondria attenuate mitochondrial-specific oxidative
damage (Subramanian et al., 2010; Oyewole and Birch-Machin,
2015; Ni et al., 2016). Finally, antioxidant in excess should
have detrimental effects on intracellular redox signaling, a
ROS-mediated process that positively regulates a vast array of
signaling pathways (Ristow et al., 2009).
Recent findings revealed that not only elevated ROS are
critical to cardiac diseases, but accumulation of endogenous toxic
aldehydes also plays detrimental role in the cardiovascular system
(Chen et al., 2010; Chen and Zweier, 2014). 4-hydroxynonenal
(4-HNE), a major end-product of peroxidative degradation
of mitochondrial phospholipids, is a highly reactive aldehyde
that readily forms protein adducts via the Michael addition
(Roede and Jones, 2010). Accumulation of 4-HNE causes cardiac
mitochondrial dysfunction in a dose-dependent manner and
contributes to cardiac pathophysiology in rodents (Campos
et al., 2012; Gomes et al., 2014, 2015). Excessive 4-HNE adducts
formation has also been reported in human failing hearts
(Nakamura et al., 2002; Ferreira et al., 2012) and was associated
with impaired cardiac bioenergetics, contractility properties and
proteostasis (Campos et al., 2012; Ferreira et al., 2012). Therefore,
accumulation of 4-HNE appears to be a hallmark of cardiac
diseases (Figure 1A).
Aldehyde dehydrogenase 2 (ALDH2), a member of the
aldehyde dehydrogenase family (Marchitti et al., 2008; Vasiliou
et al., 2013), is a mitochondrial tetrameric enzyme responsible
for the conversion of toxic aldehydes such as 4-HNE into
inactive acids (Perez-Miller et al., 2010; Sobreira et al., 2011;
Ferreira and Mochly-Rosen, 2012; Josan et al., 2013). ALDH2
has emerged as key enzyme in the protection of cardiac myocytes
and neurons against aldehydic overload (Sun et al., 2011; Ferreira
and Mochly-Rosen, 2012; Zambelli et al., 2014). Pharmacological
ALDH2 activation using a small molecule (Alda-1) protects
the heart against ischemia-reperfusion injury (Chen et al.,
2008, 2014; Gross et al., 2015). We have recently reported
that reducing cardiac aldehydic load via selective activation
of mitochondrial ALDH2 is sufficient to improve ventricular
function in heart failure through a better cardiac mitochondrial
bioenergetics and reduced ROS generation (Gomes et al., 2014,
2015). These findings point out ALDH2 as a critical player
in the maintenance of mitochondrial quality control, and
highlight the potential therapeutic value of ALDH2 activators in
counteracting the detrimental role of aldehydes in cardiac disease
(Figure 1A).
MITOCHONDRIAL PROTEOSTASIS
SURVEILLANCE (SECOND LEVEL OF
DEFENSE)
The endosymbiotic theory proposes that mitochondria (a former
free-living proteobacterium) were engulfed by a precursor
eukaryotic cell about 1.5 billion years ago (Gray et al., 1999).
During the evolutionary process most of the mitochondrial
genome was transferred to nuclear genome. Approximately 1100
mitochondrial proteins are encoded by the nucleus, translated
in the cytosol and imported to mitochondria (Pagliarini et al.,
2008; Baker et al., 2011). These proteins work in synchrony
with the 13 mitochondrial-encoded proteins (all subunits of the
electron transport chain) to maintain ATP production (Jovaisaite
and Auwerx, 2015). Changes in the stoichiometric balance
between nuclear- and mitochondrial-encoded proteins due to
improper mitochondrial protein import and folding, as well as
mutations in mitochondrial DNA, affect organelle proteostasis,
which is sufficient to disrupt the integrity and functionality of
mitochondria. Therefore, a network ofmitochondrial chaperones
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FIGURE 1 | (A) Reactive aldehydes in mitochondria: excessive reactive oxygen species causes lipid peroxidation and consequent generation of 4-hydroxynonenal
(4-HNE), a highly reactive aldehyde that readily forms protein adducts. Accumulation of 4-HNE adducts causes mitochondrial dysfunction and contributes to the
propagation of stress related to cardiac pathophysiology. Aldehyde dehydrogenase 2 (ALDH2) is a mitochondrial enzyme responsible for the conversion of 4-HNE into
inactive acids. (B) Mitochondrial unfolded protein response (UPRmt): Accumulation of mitochondrial unfolded proteins results in increased proteolysis and release of
mitochondrial-generated peptides to the cytosol. It is suggested that these peptides activate cytosolic transcription factors (i.e., ATFS-1, UBL-5, and DVE-1). Once
inside the nucleus, these transcription factors promote upregulation of genes involved in mitochondrial proteostasis (i.e., chaperones and proteases), thus relieving
stress and re-establishing mitochondrial homeostasis. The UPRmt has been characterized in the nematode Caenorhabditis elegans.
and proteases are crucial for maintenance of organelle protein
homeostasis.
Mitochondrial chaperones and chaperonins including
mtHsp70, Hsp60, and Hsp10 are part of mitochondrial
quality control system. These proteins assist mitochondrial
protein import machinery, protein folding, electron transport
chain assembly, and prevention of aggregation of unfolded
proteins (Baker et al., 2011; Pellegrino et al., 2013). Loss of
function of mitochondrial chaperones has been implicated
in several pathological processes including cardiovascular
diseases (MacKenzie and Payne, 2007). Elevated Hsp60 protein
levels have been reported in human failing hearts, which
might suggest a compensatory response due to disrupted
mitochondrial proteostasis (Knowlton et al., 1998). Indeed,
combined or individual overexpression of Hsp60 and Hsp10
protects mitochondrial function and prevents cardiomyocyte
death induced by either hypoxia-reoxygenation injury or
doxorubicin (Lin et al., 2001; Hollander et al., 2003; Shan et al.,
2003).
Another critical component of mitochondrial quality control
relies to proteolytic systems located at different mitochondrial
compartments. Mitochondrial proteases are required to
degrade misfolded, damaged, and unfolded proteins no longer
capable of being refolded by chaperones. Lon and ClpXP
are typical proteases located in the matrix. Lon degrades
denatured and oxidized proteins while the substrates of
ClpXP still have to be identified. Another class of proteases
is located at mitochondrial inner membrane. These AAA
metalloproteases (ATPases associated with a number of cellular
activities) expose their catalytic sites either to matrix (m-
AAA protease) or to intermembrane space (i-AAA protease)
and are involved in processing and degradation of proteins
(Griparic et al., 2007; Song et al., 2007; Bonn et al., 2011;
Gerdes et al., 2012). Both i-AAA and m-AAA proteases
mainly degrade unassembled mitochondrial intermembrane
proteins (Baker et al., 2011). Disruption of i-AAA and m-AAA
proteases affects mitochondria morphology, proteostasis, and
bioenergetics (Nolden et al., 2005; Griparic et al., 2007). Recently,
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Wai et al. demonstrated that cardiac-specific ablation of the
m-AAA protease YME1L alters mitochondrial morphology
and metabolism and causes heart failure in mice (Wai et al.,
2015).
Another important mitochondrial quality control mechanism
is characterized by an inter-organelle communication between
mitochondria and nucleus (known as mitochondrial retrograde
signaling), which regulates mitochondrial proteostasis by
upregulating nuclear-encoded mitochondrial genes (Figure 1B;
Haynes et al., 2013). This process has been characterized
and well-explored in the nematode Caenorhabditis elegans,
where disruption of mitochondrial unfolded protein response
(UPRmt) perturbs mitochondrial function and negatively
affects longevity (Haynes et al., 2010). Briefly, loss of
mitochondrial proteostasis triggers UPRmt, which may results
in accumulation of mitochondrial-derived peptides in the
cytosol and translocation of the transcriptional factor ATFS-1
to the nucleus. In association with others transcriptional factors
(UBL-5 and DVE-1), ATFS-1 promotes upregulation of genes
involved in mitochondrial proteostasis (i.e., chaperones and
proteases), glycolytic metabolism, detoxification, and innate
immune response, thus relieving stress and re-establishing
mitochondrial homeostasis (Benedetti et al., 2006; Jovaisaite
et al., 2014; Nargund et al., 2015).
Fiorese et al. recently described how UPRmt is regulated
in mammals (Fiorese et al., 2016). They suggest that ATF5, a
mammalian transcriptional factor, has a protective role during
mitochondrial dysfunction by regulating UPRmt signaling,
similar to ATFS-1 in worms. The role of UPRmt signaling
in cardiovascular diseases is unknown. It is expected that
UPRmt signaling might be activated in failing hearts or
during ischemia-reperfusion injury to compensate impaired
mitochondrial proteostasis. In fact, UPRmt activation protects
C. elegans against ischemic injury (Durieux et al., 2011; Kaufman
and Crowder, 2015).
MITOCHONDRIAL DYNAMICS AND
MITOPHAGY (THIRD LEVEL OF DEFENSE)
Mitochondria usually form a highly dynamic network that
plays crucial role in cardiac bioenergetics. The maintenance
of mitochondrial size, shape, number and location relies
to well-conserved quality control mechanisms including
mitochondrial fusion-fission machinery, and mitophagy
(Figure 2; Liesa et al., 2009; Dorn and Kitsis, 2015; Shirihai
et al., 2015). Disruption of these quality control processes result
in accumulation of abnormal mitochondria, which is likely
associated to cardiovascular diseases (Dorn, 2013; Andres et al.,
2015).
Fusion Machinery
Mitochondrial fusion is important for the exchange of
DNA, proteins and metabolites between two neighboring
mitochondria, therefore helping the maintenance of
oxidative phosphorylation, membrane potential and DNA
replication/repair (Liesa et al., 2009). Mitochondrial fusion
requires both the outer and the inner membranes of two
mitochondria to fuse (Disatnik et al., 2015). Two members of
the large GTPase dynamin family orchestrate the fusion of the
outer mitochondrial membrane (mitofusins 1 and 2—Mfn1
and Mfn2) while OPA1 (optic atrophy factor 1) mediates inner
membrane fusion (Figure 2). OPA1 is subjected to proteolytic
processing where accumulation of short forms is accompanied
by fragmentation of mitochondria network and loss of cristae
structures (Griparic et al., 2007; van der Bliek et al., 2013).
Despite of its role in regulating mitochondrial dynamics, Mfn2
also links mitochondria to the endoplasmic reticulum, a critical
process for controlling calcium handling and cell death in
cardiomyocytes (Dorn et al., 2015).
Mitochondrial fusion is critical for heart physiology.
Combined Mfn1 and Mfn2 ablation of mouse hearts results
in accumulation of fragmented mitochondria and leads to
heart failure (Chen et al., 2011). Of interest, Hall et al. recently
demonstrated that double Mfn1/Mfn2 knockout animals are
protected from acute ischemia-reperfusion due to impaired
mitochondria/sarcoplasmic reticulum tethering (Hall et al.,
2016). These findings suggest that Mfn1 and Mfn2 may
play either protective or detrimental role according to stress
condition. Disruption of mitochondrial dynamics through
deletion of OPA1 or imbalanced OPA1 processing also causes
mitochondrial fragmentation, bioenergetics deficit and heart
failure in mice (Chen et al., 2012; Wai et al., 2015). Overall,
enzymes that control mitochondrial fusion are critical for the
maintenance of bioenergetics, cellular viability, and cardiac
function. Therefore, pharmacological and non-pharmacological
interventions that modulate Mfn1, Mfn2 and OPA1 may have
cardioprotective effects against acute and chronic pathological
conditions.
Fission Machinery
Fission is critical for segregating dysfunctional mitochondria,
where the impaired daughter organelle can be either
recovered by fusing with healthy mitochondria or eliminated
through autophagy (Gottlieb and Bernstein, 2016; Figure 2).
Mitochondrial fission is triggered by dynamin-related protein
1 (Drp1). Upon activation, Drp1 translocates from the cytosol
to the outer mitochondria membrane, binds to adaptor proteins
and constrict both mitochondrial outer and inner membranes
(Suzuki et al., 2005; Otera et al., 2010). Impaired mitochondrial
fission due to a missense mutation in Dnm1 (Drp1) causes
progressive energy deficient and dilated cardiomyopathy in
rodents (Ashrafian et al., 2010).
Excessive mitochondrial fission has a negative impact on
heart during ischemia-reperfusion injury (Disatnik et al.,
2015). Inhibition of mitochondrial fission using a dominant-
negative mutant form of Drp1 protects cultured cardiomyocytes
against hypoxia-reoxygenation stress (Ong et al., 2010). More
recently, we demonstrated that the use of a selective inhibitor
of the fission machinery (p110 peptide; Qi et al., 2013),
which inhibits the interaction of fission proteins Fis1/Drp1,
decreases mitochondrial fission and improves bioenergetics
in different models of ischemia-reperfusion injury, including
primary cardiomyocytes, ex vivo heart model, and an in vivo
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FIGURE 2 | (A) Mitochondrial fusion-fission balance: Mitochondrial fission: Drp1 translocates to mitochondria and binds to Fis1 to promote fission. Daughter
mitochondria can be recovered or removed. Recovered mitochondria re-enter in the life cycle to fuse with healthy mitochondria. Mitochondrial fusion: outer membrane
fusion is regulated by Mfn1 and Mfn2, while OPA1 is responsible for inner mitochondrial membrane fusion. (B) Mitophagy: damaged mitochondria can be sequestered
by autophagosomes. The autophagosomes then fuse with lysosomes to degrade sequestered mitochondria.
myocardial infarction model (Disatnik et al., 2013). Of interest,
a single dose of p110 peptide at reperfusion after transient
coronary artery occlusion is sufficient to inhibit excessive
mitochondrial fragmentation, increase mitochondrial oxygen
consumption, and improve cardiac function in the long-
term (Disatnik et al., 2013). Together, these studies provide
evidence that blocking excessive mitochondrial fission protects
the heart against acute ischemia-reperfusion injury in rodents.
Therefore, therapies capable of reducing excessive mitochondrial
fragmentation may become a valuable tool against myocardial
infarction.
Mitophagy
Accumulation of dysfunctional mitochondria is suggested
to play a key role in cardiac pathophysiology. Therefore,
turnover of mitochondria is necessary to maintain cardiac
homeostasis. Impaired mitochondria can be selectively targeted
and eliminated through a process termed mitochondrial
autophagy (mitophagy; Figure 2B). Briefly, in healthy
mitochondria PINK1 (PTEN-induced putative kinase 1)
is targeted to the mitochondrial inner membrane where
it is degraded. During stress, dissipation of mitochondrial
membrane potential results in accumulation of PINK1 on the
mitochondrial surface, which phosphorylates/activates the E3
ubiquitin ligase Parkin (Kane et al., 2014). Parkin ubiquitinates
key proteins that can be degraded by the proteasome or
recognized by autophagy adaptor proteins. These adaptor
proteins are able to act as cargo receptors, which recruit them
to autophagosomes (Lazarou et al., 2015). The autophagosomes
then fuse with lysosomes to degrade sequestered mitochondria
(Figure 2B; Youle and Narendra, 2011). This process is known
as macroautophagy. Mitochondria can also be directly engulfed
through membrane invagination by lysosome, a process called
microautophagy (Yogalingam et al., 2013; Hwang et al., 2015).
Both macroautophagy and microautophagy are critical to
remove damaged mitochondria during cardiac stress (Disatnik
et al., 2015).
Markers of autophagy are upregulated in cardiac diseases
(Nakai et al., 2007; Zhu et al., 2007) However, accumulation
of these proteins may reflect either increased or insufficient
autophagy flux (Klionsky et al., 2016). Studies using
genetically modified animals provide evidence that autophagy
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is critical for the maintenance of cardiac homeostasis
(Kubli et al., 2013; Gong et al., 2015). Tissue-specific
knockout of autophagy-related genes causes accumulation
of disorganized mitochondria and oxidative stress (Tanaka
et al., 2000; Wu et al., 2009) whereas overexpression of
these genes ameliorates cardiomyopathy (Bhuiyan et al.,
2013).
Disruption of mitophagy in Parkin-deficient hearts is
sufficient to cause accumulation of dysfunctional mitochondria,
oxidative stress, apoptosis, left ventricular dysfunction, and
pathological cardiac hypertrophy (Gong et al., 2015). Moreover,
defective mitophagy exacerbates cardiac damage induced by
myocardial infarction (Narendra et al., 2008). These findings
suggest that proper elimination of damaged mitochondria
during stress conditions (i.e., myocardial infarction or heart
failure) protect against oxidative stress and apoptosis; therefore
contributing to the maintenance of cardiac physiology. Of
interest, mitophagy markers are reduced in end-stage human
heart failure (Billia et al., 2011). Saito et al. recently demonstrated
that reduced autophagic vacuoles in cardiomyocytes are
associated with poor heart failure prognosis in humans (Saito
et al., 2016).
Finally, mitophagy seems to play a critical role during acute
cardiac ischemia-reperfusion injury, a process characterized by
accumulation of damaged mitochondria and severe oxidative
stress. Pharmacological upregulation of autophagy prevents
the onset of cell death following ischemia-reperfusion injury
(Hamacher-Brady et al., 2006; Sala-Mercado et al., 2010;
Yogalingam et al., 2013). However, future studies are required to
test whether this cardioprotective effect occurs through enhanced
clearance of damaged mitochondria. Of interest, depletion of
either Parkin or p62/SQTSTM1 is sufficient to abolish the
cardioprotective effects of both ischemic preconditioning and
simvastatin treatment in rodents (Huang et al., 2011; Andres
et al., 2014).
SUMMARY AND PERSPECTIVES
Mitochondria are essential organelles for the maintenance of
myocardial homeostasis. They play critical role in bioenergetics,
redox balance, ion homeostasis, and cell death. The importance
of functional mitochondrial to the heart has been highlighted by
the fact that situations that lead to mitochondrial dysfunction
are often associated with cardiac diseases. Many of these
diseases manifest later in life, where mitochondria seems to
be less functional. Therefore, different levels of mechanisms of
surveillance and quality control capable of detecting and fixing
defects that affect mitochondrial performance are critical for the
maintenance of long-lived cells with high energy demand such
as cardiomyocytes. The central role of mitochondrial quality
control in the health of myocardium has been recently reported.
As described above, the machinery regulating mitochondrial
quality control including mitochondrial redox balance, aldehyde
metabolism, proteostasis, dynamics, and clearance are potential
novel therapeutic targets for cardiac diseases. However, future
research focusing on the critical molecular events involved
in mitochondrial quality control is needed to develop better
pharmacological interventions.
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